Skip to main content
B

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,648 across all filing types
Latest filing 2026-04-24 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
未来三年股东分红回报规划（2026年-2028年）
Governance Information Classification · 1% confidence The document is not reporting actual financial results or announcing a dividend payment; rather, it lays out the company’s internal policy and multi-year plan for shareholder dividend distribution (2026–2028), including governance procedures, decision-making processes, and policy principles. This is clearly a corporate governance policy document, fitting the Governance Information category.
2026-04-24 Chinese
2025年度独立董事述职报告（于李胜）
Governance Information Classification · 1% confidence The document is an annual report by an independent director on their duties, attendance, committee participation, and governance oversight for the 2025 fiscal year. It is not a full annual financial report (10-K/Annual Report), nor an earnings release, financing update, or proxy statement. Instead, it relates to the company’s corporate governance practices and the independent director’s fulfillment of governance responsibilities. Hence, it best fits the Governance Information category (CGR).
2026-04-24 Chinese
2025年度环境、社会和公司治理（ESG）报告中文版
Environmental & Social Information Classification · 1% confidence The document is titled “2025年度环境、社会和公司治理报告” (Environmental, Social & Governance Report) and contains detailed sections on ESG management, governance, social responsibility, environmental compliance, and sustainability metrics. It is a comprehensive sustainability/ESG disclosure rather than a financial earnings release or regulatory notice. This matches the definition of Environmental & Social Information (Code: SR).
2026-04-24 Chinese
关于补选第四届董事会非独立董事、调整专门委员会委员及聘任高级管理人员的公告
Board/Management Information Classification · 1% confidence The document is an official company announcement detailing the election of a non-independent director, adjustments to board committees, and appointments of senior management. It does not present financial results or report publication nor is it a full report like an annual or interim report. It clearly falls under changes to the board of directors and senior management, matching the "Board/Management Information" category.
2026-04-24 Chinese
关于2025年度拟不进行利润分配的公告
Notice of Dividend Amount Classification · 1% confidence The document is an official announcement by Shenzhen BGI Genomics Co., Ltd. regarding its 2025 profit distribution plan, explicitly stating no cash dividend, no bonus shares, and no capital reserve conversion. It details board and committee approvals and the rationale under relevant corporate and listing rules. This matches the "Notice of Dividend Amount" category, which covers announcements of dividend (or non-dividend) distribution decisions. Therefore, the correct classification is DIV.
2026-04-24 Chinese
2025年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 1% confidence The document is titled as a “special explanation” of non-operating fund occupation and related-party fund transactions for the 2025 fiscal year, prepared per the Listing Supervision Guide and signed by the external auditor (Ernst & Young Hua Ming). It supplements the audited financial statements and provides a detailed summary table of related-party fund movements. This is not a full Annual Report or earnings release, but a standalone audit-related disclosure. Therefore, it falls under the “Audit Report / Information” category.
2026-04-24 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.